Insights & Resources – COD Research – Designing Therapies For Future

Medical Affairs

CT Quality Assurance

Clinical Services

Biometrics

Transforming Complexity into Success: A Large-Scale Global Phase III Biosimilar Dermatology Trial

Strategic Planning for Patient Recruitment

Pulmonary Disease Introduction: Prevalence, Causes, Prevention & Treatment

EMA
FDA
MHRA

Human medicines European public assessment report (EPAR): Lacosamide UCB, lacosamide, Date of authorisation: 26/08/2019, Revision: 8, Status: Authorised
Source: EMA Published on 2025-05-23
Human medicines European public assessment report (EPAR): Ovitrelle, choriogonadotropin alfa, Date of authorisation: 02/02/2001, Revision: 23, Status: Authorised
Source: EMA Published on 2025-05-23
Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Date of authorisation: 17/08/2022, Revision: 11, Status: Authorised
Source: EMA Published on 2025-05-23
Human medicines European public assessment report (EPAR): Advate, octocog alfa, Date of authorisation: 02/03/2004, Revision: 34, Status: Authorised
Source: EMA Published on 2025-05-23
Human medicines European public assessment report (EPAR): Pedmarqsi, sodium thiosulfate, Date of authorisation: 26/05/2023, Revision: 5, Status: Authorised
Source: EMA Published on 2025-05-23
Human medicines European public assessment report (EPAR): Remsima, infliximab, Date of authorisation: 10/09/2013, Revision: 44, Status: Authorised
Source: EMA Published on 2025-05-23

Read More